Palatin Reports Results Of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial In Patients With Dry Eye Disease; On An Intent-To-Treat Analysis, Co-primary Sign Endpoint And Secondary Sign Endpoints Not Met

Author: Benzinga Newsdesk | February 28, 2024 08:34am

On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025). PL9643 treatment for the co-primary sign endpoint and secondary sign endpoints demonstrated positive treatment effects over vehicle in the ITT population but did not achieve statistical significance. In the unadjusted planned analyses, the co-primary endpoints and secondary endpoints did not reach statistical significance.

Posted In: PTN